GlassScriptPhysician profile
Maria Dungo
NPI 1235101874
$6,968.58
in general payments reported to CMS, 2019-2025
24 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $66.51 · 2021: $270 · 2022: $126 · 2023: $5,207 · 2024: $24.13 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,270 · Travel and Lodging: $718 · Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,270.00 |
| Travel and Lodging | $718.44 |
| Food and Beverage | $403.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,200.34 | 2021-2023 | Trodelvy |
| Janssen Pharmaceuticals, INC | $191.79 | 2019-2021 | |
| Astellas Pharma US INC | $191.06 | 2019-2024 | Padcev |
| Pfizer INC. | $167.60 | 2019-2025 | |
| Amgen INC. | $165.36 | 2019-2021 | |
| Lilly USA, LLC | $150.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $139.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $101.87 | 2019-2025 | Lynparza, Keytruda |
| Comsort, INC | $100.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $81.23 | 2019-2025 | Opdivo |
| Incyte Corporation | $66.62 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $63.62 | 2019 | |
| Glaxosmithkline, LLC. | $59.67 | 2025 | Blenrep, Ojjaara |
| Celgene Corporation | $55.70 | 2019-2022 | |
| Seagen INC. | $48.95 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.03 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $35.92 | 2019-2021 | |
| Myovant Sciences INC. | $27.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.19 | 2019 | |
| Janssen Biotech, INC. | $22.01 | 2019-2023 | Imbruvica |
| Sirtex Medical INC | $17.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Dungo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.